DARPP-32 and t-DARPP isoform in non-small cell lung cancer (NSCLC): could they drive patients’ clinical management and be a therapeutic target?

Lung cancer remains the main cause of cancer-related death worldwide (1). In the last decade, the most significant improvements in non-small cell lung cancer (NSCLC) have been made through identification and exploiting of novel therapeutic targets. Among them, sensitizing null EGFR null mutations, null ALK null and null ROS-1 null gene rearrangements are the main targetable alterations that have deeply changed both clinical management and...